Preview Newsletter
XARELTO Media Monitoring – Week of 5-20-16
-
Xarelto Lawsuit Plaintiffs Claim Manufacturer Is Responsible For Death of Family Members
May 19, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a wrongful death lawsuit filed in St. Clair County Circuit Court on November 20, 2015. The plaintiffs, in this case, are comprised of 10 people living in different states claiming that family members died from excessive bleeding from taking Xarelto. Their suit is against Janssen Pharmaceuticals, a subdivision of the Johnson and Johnson Corporation, and Bayer AG the manufacturers of Xarelto -
Studies On Blood Thinner Support Claims Made By Xarelto Lawsuit Plaintiffs
May 18, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on independent studies related to the effects of the blood thinner Xarelto on patients using the drug. A particular study done by two doctors, Judy Hun and John Hwang, investigated the impact the drug had on their patients after some reported that they suffered from eye bleeding, otherwise known as “spontaneous vitreous hemorrhage.” After their study, they concluded that the risk of this type of eye bleeding may be increased in patients that switched from the more traditional blood thinners to Xarelto. -
Xarelto Lawsuit Plaintiffs Find Support In Studies Conducted On Anticoagulant
May 18, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on lawsuits that are underway against the manufacturers of Xarelto, with 550 cases in a mass tort group in Philadelphia, PA along with an additional 2,800 cases in a multidistrict litigation (number 2592) in Louisiana consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPMDL) and overseen by the Honorable Judge Eldon Fallon. -
Xarelto Lawsuit Plaintiffs Allege Drug Caused Fatal Side Effects In Family Members
May 18, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a new lawsuit filed against the makers of Xarelto, Bayer AG and Janssen Pharmaceuticals, a subsidiary company of the Johnson and Johnson Corporation. The suit alleges that because of deceptive marketing using celebrities as spokespersons, the public was not sufficiently informed about the potentially dangerous side effects of taking Xarelto. It is alleged that despite the company’s research showing otherwise, the makers of the drug knowingly and fraudulently depicted it as a safe option for patients that had undergone knee and hip replacement procedures or were dealing with a medical condition impacting the heart called atrial fibrillation. -
Family Members File Xarelto Lawsuit Claiming Drug Caused Fatal Side Effects
May 19, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on claims made by plaintiffs in a new lawsuit filed against the makers of Xarelto, Janssen Pharmaceuticals, and Bayer AG. The U.S. Food and Drug Administration (FDA) had sent the manufacturers written correspondence stating that claims made in their marketing campaign for Xarelto were misleading. However, despite the FDA letter, plaintiffs allege that Bayer and Janssen continued to advertise the blood thinner with no amendments made to their public outreach. -
Several Xarelto Lawsuit Plaintiffs Note Studies Conducted On Drug Which Support Their Claims
May 18, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the number of lawsuits which have been filed against Xarelto manufacturers and independent studies that have linked the drug to excessive bleeding. To date, there have been well over 2,800 federal cases filed that have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPMDL). The multidistrict litigation (MDL) number 2592 is being overseen by the Honorable Judge Eldon Fallon in Louisiana. There is also a mass tort program in Philadelphia, PA with 550 cases filed against the drug manufacturers. -
Xarelto Lawsuit Plaintiffs Note Similarities To Pradaxa Cases
May 13, 2016 | BloodThinnerHelp.com
By John Osborne
BloodThinnerHelp.com reports on the U.S. Judicial Panel on Multidistrict Litigation(JPMDL) and its decision to consolidate 2,800 lawsuits filed against the manufacturers of Xarelto, a new-generation blood-thinning drug. Janssen Pharmaceuticals and Bayer AG are the defendants in all the cases. All plaintiffs involved are alleging strikingly similar complaints that the drug precipitated spontaneous and fatal uncontrollable internal and external bleeding. -
Xarelto Lawsuit Plaintiffs Find Support In Studies Completed On The Drug
May 17, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on Xarelto, a blood thinner drug approved for use in 2011 by the U.S. Food and Drug Administration (FDA). Xarelto was released on the market to treat patients who may be at an increased risk of blood clots or stroke due to medical conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism or those who are recovering from surgeries for hip or knee replacements. The drug was hailed as a new-generation blood thinner, but it was not soon after its release that the public began to hear about links to potentially dangerous side effects of the drug -
Previous Pradaxa Settlement Gives Hope To Xarelto Lawsuit Plaintiffs
May 13, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the consolidation of the numerous lawsuits that have been filed against the manufacturers of Xarelto, Janssen Pharmaceuticals a subsidiary company of the Johnson and Johnson Corporation and Bayer AG. The U.S. Judicial Panel on Multidistrict Litigation (JPMDL) decreed that since the cases filed were strikingly similar in the allegations being leveled at the manufacturers related to the onset of uncontrollable bleeding, it consolidated the cases together, which now number over 2,800 complaints. In the month of August 2015 alone, the cases included in the multidistrict litigation (MDL) have grown by 400 cases and are expected to increase further. -
Xarelto Lawsuit: Man Suffers from Gastrointestinal Bleeding
May 17, 2016 | Top Class Actions
By Tamara Burns
A Pennsylvania man has filed a Xarelto lawsuit against Janssen Pharmaceuticals, alleging the blood thinning medication caused his gastrointestinal bleeding. -
Xarelto Bleeding Risks Result in Xarelto Lawsuit Surge
May 19, 2016 | Legal Examiner
By Laurence Banville
TheProductLawyers.com comments on the increasing number of lawsuits being filed regarding Xarelto, a popular blood-thinning agent. Originally approved by the FDA in 2011, the drug has since garnered negative attention from both public and professional quarters. It was a popular alternative to other more traditional anticoagulants, largely because it required no drastic dietary alteration, little monitoring, and no adjustment to dosage -
VA Woman Sues Xarelto Makers Over Bleeding Risks
May 14, 2016 | Righting Injustice
By Jennifer Walker-Journey
Virginia resident Jean Coltes is suing the makers of the blood thinner Xarelto, claiming the medication caused her to bleed internally.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Stories Below
-
Xarelto Lawsuit Plaintiffs Claim Manufacturer Is Responsible For Death of Family Members
May 19, 2016 | BloodThinnerHelp.com
By Joseph Osborne
May 19, 2016 – /PressAdvantage/ – BloodThinnerHelp.com reports on a wrongful death lawsuit filed in St. Clair County Circuit Court on November 20, 2015. The plaintiffs, in this case, are comprised of 10 people living in different states claiming that family members died from excessive bleeding from taking Xarelto. Their suit is against Janssen Pharmaceuticals, a subdivision of the Johnson and Johnson Corporation, and Bayer AG the manufacturers of Xarelto.
Xarelto lawsuits now exceed 3,000 cases, with 2,800 being consolidated in a federal court in Louisiana and an additional 550 in Philadelphia, PA that have been joined together in a mass tort program.
The plaintiffs also allege that Janssen and Bayer misled the public through its marketing and advertising which utilized celebrities to endorse and discuss the product. Details outlined in the court filing suggest that Bayer and Janssen clearly chose to market Xarelto as an effective and safe treatment for patients who required knee and hip replacements or for those who suffered from a common heart ailment called atrial fibrillation.The plaintiffs state the manufacturers falsely represented the drug and did not sufficiently mention the potentially dangerous side effects that could result from taking it.
In June 2013, the U.S. Food and Drug Administration contacted Bayer and Janssen via written correspondence stating that the public claims made in their advertising and marketing were not accurate. However, despite the FDA’s concern as expressed in its letter, the drug continued to be promoted as it had been with no changes made to the marketing strategy by the defendants.
The plaintiffs in the St. Clair County Circuit Court filing are requesting a minimum $50,000 for each family member that had died to cover medical bills, funeral costs, legal fees and compensation for pain and suffering endured by those family members left behind. Janssen and Bayer are being charged with 9 counts of various charges ranging from fraud to wrongful death.
The Osborne firm is offering free consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. Call (866) 425-8902 for more information about this release or the Xarelto litigation.
http://www.cbs19.tv/story/32021962/xarelto-lawsuit-plaintiffs-claim-manufacturer-is-responsible-for-death-of-family-members
-
Studies On Blood Thinner Support Claims Made By Xarelto Lawsuit Plaintiffs
May 18, 2016 | BloodThinnerHelp.com
By Joseph Osborne
May 18, 2016 – /PressAdvantage/ – BloodThinnerHelp.comreports on independent studies related to the effects of the blood thinner Xarelto on patients using the drug. A particular study done by two doctors, Judy Hun and John Hwang, investigated the impact the drug had on their patients after some reported that they suffered from eye bleeding, otherwise known as “spontaneous vitreous hemorrhage.” After their study, they concluded that the risk of this type of eye bleeding may be increased in patients that switched from the more traditional blood thinners to Xarelto.
Another study that began on October 1, 2010, examined a large sample of 46,000 patients who had used one of three blood thinner drugs including Xarelto, Pradaxa, and warfarin. When the results were analyzed, it was concluded that there was “a more than twofold higher risk of bleeding with rivaroxaban (Xarelto) when compared with warfarin.” The study concluded on March 31, 2012.
These studies have produced new concerns over the safety of Xarelto and have linked the drug to sudden and uncontrollable bleeding in those who have taken it. Many patients who have filed lawsuits against the drug’s manufacturers have used these studies to support their cases in court.
To date, lawsuits filed against the manufacturers of the drug have exceeded 2,800 cases in federal court and have been consolidated into a multidistrict litigation (MDL) number 2592. The MDL is being overseen by the Honorable Judge Eldon Fallon in Louisiana. Additionally, another 550 cases have been grouped together in a mass tort program in Philadelphia, PA.
Xarelto was approved by the U.S. Food and Drug Administration (FDA) in 2011. The FDA approved the drug to treat patients that were at an increased risk of stroke or blood clots due to various medical conditions such as deep vein thrombosis, pulmonary embolism, and atrial fibrillation and those recovering from hip or knee replacement surgeries.
The Osborne firm is offering free consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. Call (866) 425-8902 for more information about this release or the Xarelto litigation.
http://www.wandtv.com/story/32012770/studies-on-blood-thinner-support-claims-made-by-xarelto-lawsuit-plaintiffs
-
Xarelto Lawsuit Plaintiffs Find Support In Studies Conducted On Anticoagulant
May 18, 2016 | BloodThinnerHelp.com
By Joseph Osborne
May 18, 2016 – /PressAdvantage/ – BloodThinnerHelp.com reports on lawsuits that are underway against the manufacturers of Xarelto, with 550 cases in a mass tort group in Philadelphia, PA along with an additional 2,800 cases in a multidistrict litigation (number 2592) in Louisiana consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPMDL) and overseen by the Honorable Judge Eldon Fallon.
Xarelto was approved by the U.S. Food and Drug Administration (FDA) in 2011 to treat patients who were at an increased risk of stroke or blood clots due to various medical conditions or recovering from surgical procedures. Patients suffering from deep vein thrombosis, pulmonary embolism or atrial fibrillation or those who required hip or knee replacement surgery were likely to receive the blood-thinning drug Xarelto. As a new-generation blood thinner drug, it was met with a lot of excitement upon its release on the market. However, it was not long after its release that patients began to experience potentially life-threatening side effects related to dangerous and sudden instances of uncontrollable bleeding which they linked to use of the drug.
Patients have used a number of studies that have been conducted on these various side effects to support their cases in court. One such study was done by two doctors of their own prompting. Judy Hun and John Hwang began to notice that many of their patients taking Xarelto began to suffer from episodes of eye bleeding, otherwise known as “spontaneous vitreous hemorrhage.” After their own investigation, they concluded that the risk of eye bleeds could be increased in those patients taking Xarelto.
Another study conducted over the course of almost two years beginning on October 1, 2010, and concluding on March 31, 2012, evaluated the potential linkage of excessive bleeding to Xarelto. The study evaluated almost 46,000 users of blood-thinning drugs such as warfarin, Pradaxa, and Xarelto. The primary conclusion was that the use of Xarelto produced much higher levels of uncontrollable bleeding than the other blood-thinning drugs included in the study.
The Osborne firm is offering free consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. Call (866) 425-8902 for more information about this release or the Xarelto litigation.
http://www.keyc.com/story/32011878/xarelto-lawsuit-plaintiffs-find-support-in-studies-conducted-on-anticoagulant
-
Xarelto Lawsuit Plaintiffs Allege Drug Caused Fatal Side Effects In Family Members
May 18, 2016 | BloodThinnerHelp.com
By Joseph Osborne
May 19, 2016 – /PressAdvantage/ – BloodThinnerHelp.com reports on a new lawsuit filed against the makers of Xarelto, Bayer AG and Janssen Pharmaceuticals, a subsidiary company of the Johnson and Johnson Corporation. The suit alleges that because of deceptive marketing using celebrities as spokespersons, the public was not sufficiently informed about the potentially dangerous side effects of taking Xarelto. It is alleged that despite the company’s research showing otherwise, the makers of the drug knowingly and fraudulently depicted it as a safe option for patients that had undergone knee and hip replacement procedures or were dealing with a medical condition impacting the heart called atrial fibrillation.
The U.S. Food and Drug Administration (FDA) pursued this argument as well. In June 2013, it had sent written correspondence to Bayer and Janssen stating that the marketing of the drug was misleading and that it needed to change. Both Bayer and Janssen ignored the FDA’s letter and continued their marketing of Xarelto with no changes.
Relatives of deceased family members filed a wrongful death lawsuit in St. Clair County Circuit Court on November 20, 2015. There are 10 plaintiffs in this particular case, residing in different states, but all are alleging that their family members’ deaths were precipitated by their use of Xarelto when it caused fatal bleeding.
The plaintiffs, in this case, are requesting at least a minimum payment of $50,000 for each deceased family member with the purpose of covering medical bills, funeral expenses, legal fees and other such costs to compensate for the pain and suffering endured by those family members left behind. There have been 9 counts of misconduct ranging from wrongful death to fraud.
In addition to this case, there have been many others filed all across the country. In Philadelphia, PA there is a mass tort program of 550 cases. In addition, there is a federal multidistrict litigation (MDL) numbered 2592 underway in Louisiana encompassing well over 2,800 cases.
The Osborne firm is offering free consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. Call (866) 425-8902 for more information about this release or the Xarelto litigation.
http://www.fox8live.com/story/32021951/xarelto-lawsuit-plaintiffs-allege-drug-caused-fatal-side-effects-in-family-members
-
Family Members File Xarelto Lawsuit Claiming Drug Caused Fatal Side Effects
May 19, 2016 | BloodThinnerHelp.com
By Joseph Osborne
May 19, 2016 – /PressAdvantage/ – BloodThinnerHelp.com reports on claims made by plaintiffs in a new lawsuit filed against the makers of Xarelto, Janssen Pharmaceuticals, and Bayer AG. The U.S. Food and Drug Administration (FDA) had sent the manufacturers written correspondence stating that claims made in their marketing campaign for Xarelto were misleading. However, despite the FDA letter, plaintiffs allege that Bayer and Janssen continued to advertise the blood thinner with no amendments made to their public outreach.
This newest wrongful death lawsuit centers on false claims made by the manufacturers of the drug and was filed on November 20, 2015, in St. Clair County Circuit Court by a group of 10 people whose family members had died from excessive bleeding allegedly through the use of Xarelto. All of the plaintiffs live in different states but they are cohesive in their claims that Xarelto caused the death of their loved ones.
In addition to this particular case, Xarelto lawsuits number in excess of 3,000 cases with over 2,800 as part of a multidistrict consolidation (MDL 2592) in a Louisiana federal court. 550 more cases have been grouped in a mass tort program in Philadelphia, Pennsylvania.
The court documents state that although Bayer and Janssen were aware of the possible dangerous side effects of the drug, they nonetheless marketed Xarelto as a safe and effective treatment for those suffering from a heart condition called atrial fibrillation and for those who had undergone knee and hip replacement surgeries. Plaintiffs claim Bayer and Janssen falsely promoted the drug using celebrity spokespersons and failed to adequately express to the public potentially dangerous side effects of the drug.
Nine counts of misconduct have been filed by the plaintiffs ranging from wrongful death to fraud and they are additionally seeking compensatory damages of $50,000 per deceased family member.
The Osborne firm is offering free consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. Call (866) 425-8902 for more information about this release or the Xarelto litigation.
http://www.newschannel6now.com/story/32021948/family-members-file-xarelto-lawsuit-claiming-drug-caused-fatal-side-effects
-
Several Xarelto Lawsuit Plaintiffs Note Studies Conducted On Drug Which Support Their Claims
May 18, 2016 | BloodThinnerHelp.com
By Joseph Osborne
May 18, 2016 – /PressAdvantage/ – BloodThinnerHelp.com reports on the number of lawsuits which have been filed against Xarelto manufacturers and independent studies that have linked the drug to excessive bleeding. To date, there have been well over 2,800 federal cases filed that have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPMDL). The multidistrict litigation (MDL) number 2592 is being overseen by the Honorable Judge Eldon Fallon in Louisiana. There is also a mass tort program in Philadelphia, PA with 550 cases filed against the drug manufacturers.
The blood-thinning drug Xarelto was approved by the U.S. Food and Drug Administration (FDA) in 2011 and was released on the market to treat patients who were susceptible to blood clots and stroke due to hip or knee replacement surgeries, and for various medical conditions such as deep vein thrombosis, pulmonary embolism, and atrial fibrillation. After its release, however, the drug became associated with some possible side effects that proved to be potentially dangerous and life-threatening.
In response to these reports of linked side effects, a number of independent studies were conducted to further investigate claims that were being made that Xarelto caused excessive bleeding, which are now also being used by Xarelto plaintiffs in their cases against the manufacturers of the drug. The first was done by two doctors, Judy Hun and John Hwang, that began to see some patients suffering instances of eye bleeding. After the doctors completed their study they concluded that the eye bleeding was precipitated when those using other more traditional blood thinner medications switched to Xarelto.
Another study done between October 1, 2010, and March 31, 2012, examined the use of three blood thinner drugs, specifically Xarelto, warfarin and Pradaxa in a sample of 46,000 patients. The study’s results indicated that there was a much higher risk of bleeding with rivaroxaban (Xarelto) when compared with warfarin.
The Osborne firm is offering free consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. Call (866) 425-8902 for more information about this release or the Xarelto litigation.
http://www.kltv.com/story/32012769/several-xarelto-lawsuit-plaintiffs-note-studies-conducted-on-drug-which-support-their-claims
-
Xarelto Lawsuit Plaintiffs Note Similarities To Pradaxa Cases
May 13, 2016 | BloodThinnerHelp.com
By John Osborne
BloodThinnerHelp.com reports on the U.S. Judicial Panel on Multidistrict Litigation(JPMDL) and its decision to consolidate 2,800 lawsuits filed against the manufacturers of Xarelto, a new-generation blood-thinning drug. Janssen Pharmaceuticals and Bayer AG are the defendants in all the cases. All plaintiffs involved are alleging strikingly similar complaints that the drug precipitated spontaneous and fatal uncontrollable internal and external bleeding.
The cases under MDL 2592 are fast progressing toward trial under the direction and supervision of the Honorable Judge Eldon Fallon in the Eastern District of Louisiana. Judge Fallon set a deadline of January 11, 2016, to have 40 test cases compiled in a pool from which 4 would be selected as bellwether trials to begin sometime in the spring of 2017. It is expected that the number of cases will continue to expand, as in the month of August 2015 alone, 400 more were added to the MDL for litigation.
The plaintiffs in the Xarelto cases are encouraged by actions taken with a prior released blood thinner called Pradaxa, also a new-generation blood thinner. Pradaxa was released in 2010 by its manufacturer Boehringer Ingelheim. Faced with 4,000 lawsuits emanating from more than 3,500 adverse event reports of which 750 were focused on fatalities from the use of the drug, Boehringer Ingelheim opted to negotiate a settlement of $650 million to those plaintiffs who filed claims against the corporation rather than face trial. Plaintiffs in the Xarelto cases are hopeful such a settlement will be proposed by Janssen and Bayer AG.
The MDL cases are not the only ones that have been consolidated for consideration. Another group of 550 cases, also all against Janssen and Bayer, are being heard in a mass tort program in Philadelphia, PA consolidated together by the Court of Common Pleas.
The Osborne firm is offering free consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. Call (866) 425-8902 for more information about this release or the Xarelto litigation.
https://www.pressadvantage.com/story/9955-xarelto-lawsuit-plaintiffs-note-similarities-to-pradaxa-cases
-
Xarelto Lawsuit Plaintiffs Find Support In Studies Completed On The Drug
May 17, 2016 | BloodThinnerHelp.com
By Joseph Osborne
May 17, 2016 – /PressAdvantage/ – BloodThinnerHelp.com reports on Xarelto, a blood thinner drug approved for use in 2011 by the U.S. Food and Drug Administration (FDA). Xarelto was released on the market to treat patients who may be at an increased risk of blood clots or stroke due to medical conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism or those who are recovering from surgeries for hip or knee replacements. The drug was hailed as a new-generation blood thinner, but it was not soon after its release that the public began to hear about links to potentially dangerous side effects of the drug.
Medical professionals Judy Hun and John Hwang began to investigate the impact of the drug on their own patients. The doctors had noticed that some of their patients suffered from a spontaneous bleeding in their eyes while taking Xarelto. They concluded after some study, that the risk of eye bleeding may be increased due to taking Xarelto.
Another study was conducted from October 1st of 2010 to March 31st of 2012 that examined a large sample of patients across the United States who had taken various blood thinner drugs such as Xarelto, Pradaxa, or warfarin. It was found that of these 46,000 patients, there was a marked increase of gastrointestinal bleeding, as much as 50 percent, when Xarelto was used versus the use of warfarin.
All of these studies have created serious concerns over the drug’s alleged linkage to dangerous and spontaneous bleeding in patients. These concerns have prompted many lawsuits related to the drug, as well. Lawsuits number in excess of 2,800 cases in a federal multidistrict litigation (MDL) numbered 2592 being overseen by the Honorable Judge Eldon Fallon of the Eastern District of Louisiana, as well as a mass group tort of an additional 550 cases in Philadelphia, PA.
The Osborne firm is offering free consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. Call (866) 425-8902 for more information about this release or the Xarelto litigation.
-
Previous Pradaxa Settlement Gives Hope To Xarelto Lawsuit Plaintiffs
May 13, 2016 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on the consolidation of the numerous lawsuits that have been filed against the manufacturers of Xarelto, Janssen Pharmaceuticals a subsidiary company of the Johnson and Johnson Corporation and Bayer AG. The U.S. Judicial Panel on Multidistrict Litigation (JPMDL) decreed that since the cases filed were strikingly similar in the allegations being leveled at the manufacturers related to the onset of uncontrollable bleeding, it consolidated the cases together, which now number over 2,800 complaints. In the month of August 2015 alone, the cases included in the multidistrict litigation (MDL) have grown by 400 cases and are expected to increase further.
Plaintiffs in the Xarelto cases are encouraged by actions taken with another new-generation blood thinner called Pradaxa that shares many similarities with the drug Xarelto. Pradaxa was released on the market for use by consumers in 2010 by Boehringer Ingelheim. As is the case with Xarelto, Pradaxa became the focus of public attention, as it was the subject of over 3,500 adverse event reports with fatalities involved in over 750 of them and subsequently became the focus of over 4,000 lawsuits. Rather than go to trial, Pradaxa's maker opted to settle all the lawsuits with a $650 million settlement. It is the hope of many of the plaintiffs in the Xarelto cases that they will also be in receipt of a settlement by the makers of Xarelto.
The MDL cases are steadily progressing toward litigation at this time. Judge Fallon required that by January 11, 2016, 40 cases be selected to form a pool from which 4 final cases will be chosen to be prepared for bellwether trials in Spring of 2017.
It should be noted as well that in addition to the cases in MDL 2592, there is an additional group of lawsuits in excess of 550 that were consolidated into a mass tort program by the Court of Common Pleas in Philadelphia, PA. All plaintiffs in these cases have named Janssen and Bayer AG as defendants as well.
The Osborne firm is offering free consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. Call (866) 425-8902 for more information about this release or the Xarelto litigation.
Read more: http://www.digitaljournal.com/pr/2938851#ixzz49DrbEsdr -
Xarelto Lawsuit: Man Suffers from Gastrointestinal Bleeding
May 17, 2016 | Top Class Actions
By Tamara Burns
A Pennsylvania man has filed a Xarelto lawsuit against Janssen Pharmaceuticals, alleging the blood thinning medication caused his gastrointestinal bleeding.
Plaintiff Charles B. claims he began taking Xarelto in November 2014 and stopped taking the medication in December 2014 when he suffered a gastrointestinal bleed that was allegedly the direct result of using Xarelto.
What is Xarelto?
Xarelto (rivaroxaban) is an oral anticoagulant used to reduce the risk of stroke and systemic embolism in patients diagnosed with atrial fibrillation. It is also used to treat and prevent deep vein thrombosis DVT) and pulmonary embolism (PE).
The anticoagulant was introduced into the market in 2011 and was the second drug in the new class of drugs called New Oral Anticoagulants(NOAs).
Xarelto and other drugs in this new class were manufactured as alternatives to warfarin (Coumadin), an oral blood thinner that was used almost exclusively for the last 60 years.
While it was effective and had an established safety record, warfarin did have its drawbacks. Patients on warfarin had to be frequently monitored to make sure the drug was at appropriate levels. Additionally, patients had certain dietary restrictions they were required to follow.
With the new oral anticoagulants like Xarelto, there was no need for frequent monitoring or dietary changes, so this was pleasing to patients and alike.
Xarelto Side Effects
Like any blood thinning medication, Xarelto side effects include an increased risk of internal bleeding.
By the nature of the drug itself, an anticoagulant stops the blood from clotting. This is effective when trying to prevent blood clots for identified health reasons.
However, there are times when blood clotting is essential, and that is to stop bleeding before it gets out of control.
If someone has a nosebleed, for example, the body produces clotting proteins to form clots to stop the bleeding, forming a clot as a natural barrier to curtail it.
However, when these clotting factors are blocked, the body has no way to stop the bleeding on its own, leading to potentially damaging side effects.
For Xarelto and other new generation anticoagulants, internal bleeding in the brain and gastrointestinal bleeding are real causes for concern. Patients who experience bleeding events may suffer serious consequences.
With warfarin, the same risk of internal bleeding was present. However, there was a way to reverse the bleeding and allow the body to begin clotting the blood again as normal. Fresh or frozen plasma and vitamin K were used to stop internal bleeding in patients on warfarin.
With Xarelto, there is no reversal agent or bleeding antidote. Patients can only be stabilized in the hospital as they wait for the medication’s effects to wear off and the body restores the clotting.
For some, the damage done by Xarelto before hospital intervention can be too far gone, and the same can be said even with swift hospital intervention. Patients may experience severe, long-lasting damage from internal bleeding, or the situation may even be fatal for some.
Allegations in the Xarelto Lawsuit
In Charles’ Xarelto lawsuit, he brought forth twelve total counts against Janssen in response to his alleged injury caused by the drug including strict liability, failure to warn, negligence, negligent misrepresentation, fraud and violation of consumer protection laws/consumer fraud laws, among others.
Charles is seeking compensatory damages for pain, suffering, emotional distress, loss of enjoyment of life and other non-economic damages, an award for economic damages in the form of medical expenses, out of pocket expenses, lost earnings and other economic damages, and punitive damages to deter Janssen’s future conduct.
The plaintiff is also seeking pre- and post-judgment interest, attorneys’ fees and costs and other relief as deemed appropriate by the court.
The Xarelto Lawsuit is Case No. 2:2015-cv-06392 filed within the larger multidistrict litigation, In re: Xarelto(Rivaroxaban) Products Liability Litigation, MDL No. 2592 in the U.S. District Court for the Eastern District of Louisiana.
https://topclassactions.com/lawsuit-settlements/lawsuit-news/335148-xarelto-lawsuit-man-suffers-gastrointestinal-bleeding/
-
Xarelto Bleeding Risks Result in Xarelto Lawsuit Surge
May 19, 2016 | Legal Examiner
By Laurence Banville
TheProductLawyers.com comments on the increasing number of lawsuits being filed regarding Xarelto, a popular blood-thinning agent. Originally approved by the FDA in 2011, the drug has since garnered negative attention from both public and professional quarters. It was a popular alternative to other more traditional anticoagulants, largely because it required no drastic dietary alteration, little monitoring, and no adjustment to dosage.
What Is Xarelto Used For?
Physicians use it to treat a range of circulatory problems, including pulmonary embolism, deep vein thrombosis, and the prevention of strokes for those diagnosed with atrial fibrillation. It was also frequently prescribed to patients in recovery from knee and hip surgery, in order to prevent the formation of blood clots in the legs. However, the mounting body of evidence has drawn negative scrutiny from the FDA. The association has issued two black box warnings, which precede a complete product recall.
This is in response to the dire implications brought to light by several subsequent studies. Patients who did not slowly wean themselves from Xarelto and replace it with another blood thinner were shown to have an increased risk of clot development. Still other studies indicate that those switching from a traditional blood thinner regimen to one of Xarelto often developed bleeding from the stomach and eyes, even when monitored by their physician.
Current Status Of Lawsuits
As a result, more than 3,000 lawsuits have been filed against Bayer AG and Janssen Pharmaceuticals. In Louisiana, 2,800 suits were combined by the U.S. Judicial Panel for Multidistrict Litigation as MDL No. 2592. Pennsylvania has also merged 550 plaintiffs’ cases to form a mass tort litigation program in the Philadelphia Court of Common Appeals. MOst of the cases consolidated into MDL No. 2592 allege that the drug places patients in danger of sudden and catastrophic bleeding events. Additionally, they claim that the makers of the drug concealed the negative traits of Xarelto through unsound business practices, while touting its positive attributes to the public.
To date, four bellwether trials have been selected and are slated to occur in early 2017. Developments will continue to be reviewed in monthly status conferences.
http://newyorkcity.legalexaminer.com/fda-prescription-drugs/xarelto-bleeding-risks-result-in-xarelto-lawsuit-surge/
-
VA Woman Sues Xarelto Makers Over Bleeding Risks
May 14, 2016 | Righting Injustice
By Jennifer Walker-Journey
Virginia resident Jean Coltes is suing the makers of the blood thinner Xarelto, claiming the medication caused her to bleed internally.
Xarelto was approved in 2011 and is used to prevent strokes in patients with the heart rhythm abnormality atrial fibrillation, prevent and treat deep vein thrombosis and pulmonary embolism, and to prevent blood clots in patients who have recently undergone hip or knee replacement surgery.
Xarelto has been linked to life threatening bleeding events includinggastrointestinal bleeds and brain hemorrhages. There is also no antidote currently on the market to reverse the blood thinning effects of Xarelto in the event of a bleeding emergency.
Coltes says she started taking Xarelto in March 2014. A month later, she claims she was diagnosed with internal bleeding and hematuria, for which she was hospitalized. Coltes claims Xarelto was the cause of her internal bleeding, and she blames the makers of Xarelto for failing to adequately warn her or her doctors of this risk.
Coltes’ lawsuit, which was filed in the U.S. District Court for the Eastern District of Louisiana, names Janssen Research & Development LLC, Janssen Ortho LLC, Janssen Pharmaceuticals Inc., Bayer Healthcare Pharmaceuticals Inc., Bayer Pharma AG, Bayer Corp., Bayer Healthcare LLC, Bayer Healthcare AG, and Bayer AG. The lawsuit accuses the companies of strict products liability, negligence, and fraud, among other counts.
Coltes’ lawsuit is one of hundreds filed against Johnson & Johnson’s Janssen Pharmaceuticals and Bayer over bleeding risks.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Stories Below
Add recipients
Suggested